Evidence map›Paper›PMID 41271591›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Rationally Engineered Spleen-Tropic One-Component Lipid-mRNA Complex (OncoLRC) for Cancer Vaccines.

Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qimeng YinHuman Phenome Institute, Fudan University, Shanghai, 201203, China.
Chenchen ZhangHuman Phenome Institute, Fudan University, Shanghai, 201203, China.
Jiahao LiHuman Phenome Institute, Fudan University, Shanghai, 201203, China.
Kun HuangHuman Phenome Institute, Fudan University, Shanghai, 201203, China.
Min QiuHuman Phenome Institute, Fudan University, Shanghai, 201203, China.ORCID https://orcid.org/0000-0002-7373-2355

Funding

Fudan University startup fundInnovation Cooperation Project of the Greater Bay Area Institute of Precision MedicineNational Key Research and Development Program of China 2022YFC3400100National Natural Science Foundation of China 52303369Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 23ZR1405400Shanghai Pilot Program for Basic Research-Fudan University 21TQ1400100(25TQ007)
6 · The paper itself

Abstract

mRNA vaccines offer great potential for cancer immunotherapy, yet efficient delivery of antigen-encoding mRNA to antigen-presenting cells (APCs) in lymphoid organs remains a significant challenge. Here, OncoLRC is introduced, a rationally engineered, spleen-tropic, one-component lipid-mRNA complex that selectively delivers mRNA to splenic APCs following systemic administration. Through a systemic screening and optimization process, a dimethylamino (DMA)-lipidoid-based OncoLRC formulation that achieves nearly exclusive spleen-targeting mRNA delivery, outperforming its conventional four-component lipid nanoparticle (LNP) formulation counterpart has been developed. Notably, OncoLRC requires a reduced lipid-to-mRNA weight ratio of 1.5:1 compared to the typical 10:1 ratio in standard LNPs. OncoLRC formulated with ovalbumin (OVA) mRNA (OncoLRC

Indexed as

Cancer VaccinesLipidsRNA, MessengerSpleenAnimalsAntigen-Presenting CellsDendritic CellsFemaleMiceMice, Inbred C57BLNanoparticlesCancer VaccinesLipidsRNA, Messengerlipid nanoparticlesmRNA cancer vaccineone‐component lipid‐mRNA complexspleen‐targeted delivery

Identifiers

PMID41271591
PMCPMC12884810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.